Xellia Pharmaceuticals

Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing clinically effective anti-infective treatments against serious and often life-threatening infections. With over 100 years of pharmaceutical industry expertise, we are a leading developer, manufacturer and trusted supplier of fermented and semi-synthetic Active Pharmaceutical Ingredients (APIs) and finished dosage forms (FDF), and the world-leading supplier of Vancomycin and Colistimethate Sodium (CMS). Our range of anti-infective treatments combat, most types of bacterial and antibiotic-resistant infections and certain fungal diseases. We have growing sales in more than 70 countries to over 700 customers and are continually developing and expanding our product range to meet new treatment needs and to better service our customers’ requirements. This includes developing new dosage forms using Xellia’s APIs, and if required APIs sourced from our network of suppliers. To complement our dry powder fill and freeze-dried vials for injectable delivery we are also developing innovative proprietary delivery systems and formulations for topical, inhaled or injectable administration either in house or through partnerships. We also offer contract manufacturing services and custom synthesis for clinical trial material supply. Xellia is a private company, with more than 850 employees and four state-of-the-art manufacturing facilities in Norway, Denmark, Hungary and China. We operate according to current Good Manufacturing Practice (cGMP) and our facilities have received regulatory approval from all relevant authorities, including the US Food and Drug Administration (FDA). Our operational headquarters are in Copenhagen, Denmark.

show less